Veritex (VBTX) Form 144 Filed for 2,527-Share Sale via Charles Schwab
Rhea-AI Filing Summary
Form 144 notice for Veritex Holdings, Inc. (VBTX) discloses a proposed sale of 2,527 common shares through Charles Schwab, planned on 09/02/2025 on Nasdaq with an aggregate market value of $86,588.00. The filer reports acquiring 2,500 shares on 03/12/2021 via a private purchase from the issuer paid in cash and an additional 27 shares on 12/11/2023 via dividend reinvestment paid in cash. There are 54,745,471 shares outstanding per the form and no securities sold by the filer in the past three months. The filing includes the required representation that the seller has no undisclosed material adverse information.
Positive
- Complete disclosure of planned sale details: broker, sale date, quantity, and aggregate market value.
- Acquisition history provided with dates and payment method for all shares to be sold.
- No sales in past three months reported, simplifying aggregation rules under Rule 144.
Negative
- None.
Insights
TL;DR: Routine Rule 144 disclosure of a small planned sale; no recent disposals reported.
The filing describes a proposed sale of 2,527 common shares of Veritex via Charles Schwab on Nasdaq with an aggregate value of $86,588.00. Acquisition history is documented (private purchase in 2021 and dividend reinvestment in 2023) and payment was in cash. There are no reported sales in the past three months and the filer affirms no undisclosed material adverse information. As presented, this is a standard compliance disclosure rather than a material corporate event.
TL;DR: Disclosure meets Rule 144 content requirements; includes broker, dates, quantities, and acquisition details.
The form includes required broker identification, exact share counts, acquisition dates and methods, and the seller's certification regarding material adverse information. The absence of recent sales is noted. From a compliance standpoint the notice contains the elements regulators expect for a proposed sale under Rule 144; it does not indicate regulatory or disclosure risk based on the information provided.